This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Shanghai Institute of Pharmaceutical Industry. Active years: 2017.
Company Filing History:
Years Active: 2017
Title: Zhilong Ma - Innovator in Anti-Schizophrenia Drug Development
Introduction
Zhilong Ma is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds aimed at treating schizophrenia. His innovative work has the potential to improve the lives of many individuals affected by this mental health condition.
Latest Patents
Zhilong Ma holds a patent for "Benzoisothiazole compounds and methods of treating schizophrenia." This patent discloses benzoisothiazole compounds that are utilized in the preparation of anti-schizophrenia drugs. The compounds exhibit a strong affinity for dopamine D receptors and 5-HT receptors, demonstrating the ability to significantly improve symptoms of schizophrenia in relevant animal models. The compounds are characterized by good oral absorption, high safety, and minimal side effects, indicating their developmental value as new anti-neurotic disease drugs.
Career Highlights
Zhilong Ma is affiliated with the Shanghai Institute of Pharmaceutical Industry, where he conducts his research and development activities. His work is focused on creating effective treatments for mental health disorders, showcasing his dedication to advancing pharmaceutical science.
Collaborations
Zhilong Ma collaborates with notable colleagues, including Fang Liu and Ning Cui. Their combined expertise contributes to the innovative research being conducted at the Shanghai Institute of Pharmaceutical Industry.
Conclusion
Zhilong Ma's contributions to the field of anti-schizophrenia drug development highlight his role as an influential inventor. His patented compounds represent a promising advancement in the treatment of schizophrenia, with the potential to enhance patient outcomes significantly.